Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
INSPECS Group plc (SPEC.L)
Bath, GB
INSPECS Group plc designs, produces, sells, markets, and distributes fashion eyewear, lenses, and OEM products in the United Kingdom, Europe, North America, South America, Asia, Africa, and Australia. It operates through Frames and Optics; Manufacturing; and Lenses segments. The company offers its products under the retail brands, such as Barbour, Barbour International, BUFFALO David Bitton, CAT, Free Country, Henri Lloyd, Hype, JOSEPH, Lamb, Liberty, Lyle & Scott, Marc O’Polo, MINI, O’Neill, SUPERDRY, RADLEY LONDON, TALBOT RUNHOF, Ted Baker, Temperley LONDON, and Victor Rolf; and in house brands under BOTANIQ, SAVILE ROW Titanium, SAVILE ROW, BRENDEL Eyewear, FREIGEIST, HUMPHREY’S eyewear, JOS ESCHENBACH, and TITANFLEX names. INSPECS Group plc was founded in 1988 and is based in Bath, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.20% | +1.20% | +1.20% | +1.81% | +17.36% | +18.18% | +56.48% | -25.22% | -77.82% | -56.67% | -56.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-3.3% Q4'25: +2.2% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%-41.3% Q4'25: +38.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+0.9% Q4'25: -7.3% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%+3.0% Q4'25: +3.1% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%+4.6% Q4'25: +9.6% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q4'25: -0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×3.42× Q4'25: 1.71× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
61.25M
est: 48.36M (+26.6%)
|
47.42M
est: 32.50M (+45.9%)
|
182.62M
est: 178.41M (+2.4%)
|
200.96M
est: 197.33M (+1.8%)
|
203.29M
est: 195.14M (+4.2%)
|
198.26M
est: 200.50M (-1.1%)
|
191.70M
est: 192.00M (-0.2%)
|
196.00M
196.00M – 196.00M
+2.1% YoY
|
203.00M
203.00M – 203.00M
+3.6% YoY
|
| EBITDA |
8.82M
est: 1.32M (+569.7%)
|
-4.86M
est: 885.2K (-649.2%)
|
6.05M
est: 4.86M (+24.5%)
|
8.28M
est: 5.37M (+54.1%)
|
17.27M
est: 31.82M (-45.7%)
|
15.75M
est: 32.69M (-51.8%)
|
17.49M
est: 31.31M (-44.1%)
|
31.96M
31.96M – 31.96M
+2.1% YoY
|
33.10M
33.10M – 33.10M
+3.6% YoY
|
| EBIT |
6.44M
est: -1.76M (+466.2%)
|
-7.73M
est: -1.18M (-554.1%)
|
-5.06M
est: -6.49M (+21.9%)
|
-5.36M
est: -7.17M (+25.3%)
|
4.23M
est: 20.00M (-78.8%)
|
2.93M
est: 17.75M (-83.5%)
|
5.69M
est: 19.68M (-71.1%)
|
20.09M
20.09M – 20.09M
+2.1% YoY
|
20.81M
20.81M – 20.81M
+3.6% YoY
|
| Net Income |
4.91M
est: 10.24M (-52.0%)
|
-6.54M
est: 2.57M (-354.5%)
|
-4.03M
est: 13.61M (-129.6%)
|
-6.32M
est: 4.89M (-229.1%)
|
-997.0K
est: -4.11M (+75.7%)
|
-4.61M
est: 6.10M (-175.5%)
|
-6.51M
est: 5.95M (-209.5%)
|
6.96M
6.96M – 6.96M
+17.1% YoY
|
8.37M
8.37M – 8.37M
+20.2% YoY
|
| SGA |
19.72M
est: 26.46M (-25.5%)
|
23.46M
est: 17.78M (+31.9%)
|
114.23M
est: 61.91M (+84.5%)
|
123.75M
est: 107.97M (+14.6%)
|
100.66M
est: 104.09M (-3.3%)
|
100.04M
est: 106.95M (-6.5%)
|
81.69M
est: 102.42M (-20.2%)
|
104.55M
104.55M – 104.55M
+2.1% YoY
|
108.29M
108.29M – 108.29M
+3.6% YoY
|
| EPS |
0.07
est: 0.10 (-31.1%)
|
-0.13
est: 0.03 (-614.3%)
|
-0.04
est: 0.13 (-127.6%)
|
-0.07
est: 0.05 (-237.3%)
|
-0.01
est: -0.04 (+75.7%)
|
-0.05
est: 0.06 (-175.5%)
|
-0.06
est: 0.06 (-209.4%)
|
0.07
0.07 – 0.07
+17.1% YoY
|
0.08
0.08 – 0.08
+20.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Richard Charles Peck | Group Chief Executive Officer & Executive Director | 289.9K | male |
| Christopher D. Kay | Chief Financial Officer | 254.8K | male |
| Robin Bjorn Christian Totterman | Founder & Executive Director | 250.6K | male |
| Nick Youle | Head of Innovations | — | — |
| Angela Eman | Group ESG, Compliance & Risk Officer | — | — |
| Steve Tulba | Managing Director of Inspecs Division | — | male |
| Elliott Martin Glynn Smith | Secretary | — | — |
| Martin Bates | Sales Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPEC.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
